High-Dose Vitamin B6 (Pyridoxine) Displays Strong Anti-Inflammatory Properties in Lipopolysaccharide-Stimulated Monocytes.

Vitamin B6 is shown to have anti-inflammatory properties, which makes it an interesting nutraceutical agent. Vitamin B6 deficiency is well established as a contributor to inflammatory-related conditions, whilst B6 supplementation can reverse these inflammatory effects. There is less information available regarding the effects of high-dose vitamin B6 supplementation as a therapeutic agent. This study set out to examine the effects of high-dose vitamin B6 on an LPS-stimulated monocyte/macrophage cell population via an analysis of protein and gene expression using an RT2 profiler PCR array for Human Innate and Adaptive Immune responses. It was identified that high-dose vitamin B6 has a global anti-inflammatory effect on lipopolysaccharide-induced inflammation in monocyte/macrophage cells by downregulating the key broad-spectrum inflammatory mediators CCL2 , CCL5 , CXCL2 , CXCL8 , CXCL10 , CCR4 , CCR5 , CXCR3 , IL-1β , IL-5 , IL-6 , IL-10 , IL-18 , IL-23-a , TNF-α , CSF2 , DDX58 , NLRP3 , NOD1 , NOD2 , TLR-1 -2 -4 -5 -7 -8 -9 , MYD88 , C3 , FOXP3 , STAT1 , STAT3 , STAT6 , LYZ , CASP-1 , CD4 , HLA-E , MAPK1 , MAPK8 MPO , MX-1 , NF-κβ , NF-κβ1A , CD14 , CD40 , CD40LG , CD86 , Ly96 , ICAM1 , IRF3 , ITGAM , and IFCAM2 . The outcomes of this study show promise regarding vitamin B6 within the context of a potent broad-spectrum anti-inflammatory mediator and could prove useful as an adjunct treatment for inflammatory-related diseases.